Regulatory Approvals and Certifications - The company received FDA 510(k) approval for its OTC adaptive hearing aids, becoming the first Chinese hearing aid company to achieve this milestone[4]. - On November 20, 2023, the company obtained a medical device license from Health Canada[5]. - The company received multiple certifications, including MDSAP, FDA510(k), and ISO14001, enhancing its credibility in the medical device industry[43]. Research and Development - The company established both an audiology laboratory and an acoustics laboratory in 2023 to enhance its R&D capabilities[6]. - R&D expenses increased by 51.18% year-on-year to 23.60 million yuan, accounting for 13.50% of total revenue, indicating a strong commitment to innovation[42]. - The company established several laboratories and developed industry-leading technologies, including a keyless ultra-small hearing aid control technology and integrated chip technology[42]. - The company is developing new technologies, including wireless charging for hearing aids and sound wave control algorithms, aimed at improving product competitiveness[86]. Financial Performance - The company's operating revenue for 2023 was CNY 174,876,443.46, a decrease of 10.38% compared to CNY 195,132,408.42 in 2022[27]. - The net profit attributable to shareholders for 2023 was CNY 11,739,919.71, representing a significant decline of 70.87% from CNY 40,307,438.05 in 2022[27]. - The gross profit margin improved to 50.82% in 2023, up from 46.38% in 2022[27]. - The company achieved a market share of 10.20% in the export sales volume of hearing aids in China for 2023[39]. Market Expansion and Sales Strategy - The company expanded by opening 12 new stores in 2023, focusing on offline fitting services and strengthening its own brand development[8]. - The company has established partnerships with major international retailers, including Walmart and Carrefour, to expand its market presence[38]. - The company aims to expand its market presence in the Asia-Pacific, Europe, and the Middle East while collaborating with foreign technology teams[97]. Corporate Governance and Management - The company has established a relatively complete corporate governance structure, with actual controllers holding over 60% of the shares[101]. - The company has committed to avoiding competition and reducing related party transactions, ensuring compliance with legal and regulatory standards[118]. - The company has a commitment to prevent fund occupation and illegal guarantees, ensuring the protection of shareholder interests[118]. Employee and Management Changes - The total number of employees increased from 378 to 407, with a net addition of 29 employees during the reporting period[172]. - The company experienced a board reshuffle, resulting in the departure of several key personnel, including independent director Yuan Yinghong and production director Liu Xueying[164]. - New appointments include Xiong Zhihui as CTO and independent directors Qiu Xiaole and Zheng Nengheng, enhancing the company's leadership team[165]. Shareholder Returns and Equity Incentives - The profit distribution policy emphasizes cash dividends, with a minimum of 10% of distributable profits to be distributed in cash if profits are realized[133]. - The company plans to distribute at least 30% of the average annual distributable profits over the last three years in cash[133]. - The company plans to issue stock options and restricted stocks as part of its equity incentive plan, granting 675,000 restricted shares and 805,000 stock options to 58 key employees[111]. Community Engagement and Social Responsibility - The company helped promote 2,400 pounds of organic rice in rural areas, generating an income of CNY 18,000 and employing 30 individuals from impoverished regions[92]. - The company organized multiple public welfare activities, including health check-ups in Sichuan and Guizhou provinces, to assist hearing-impaired individuals[93]. Risk Management and Compliance - The company has not identified any significant defects in its accounting, financial management, or risk control systems during the reporting period[181]. - The supervisory board found no significant risk issues during its oversight activities in the reporting period, indicating a stable operational environment[200].

证券代码：872925 证券简称：锦好医疗 公告编号： 2024-008 惠州市锦好医疗科技股份有限公司 投资者关系活动记录表 公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、投资者关系活动类别 □特定对象调研 □业绩说明会 □媒体采访 现场参观 □新闻发布会 □分析师会议 □路演活动  其他（线下投资者调研会议） ...

证券代码：872925 证券简称：锦好医疗 公告编号：2024-009 惠州市锦好医疗科技股份有限公司 简式权益变动报告书 信息披露义务人及其主要负责人保证公告内容不存在虚假记载、误导性 陈述或者重大遗漏。 信息披露义务人保证除本报告书披露的信息外，没有通过任何其他方式 增加或减少其在上市公司中拥有权益的股份。 上市公司名称：惠州市锦好医疗科技股份有限公司 股票上市地点：北京证券交易所 股票简称：锦好医疗 股票代码：872925 信息披露义务人：浙江浩坤昇发资产管理有限公司 执行事务合伙人：张门发 住所：浙江省杭州市临平区南苑街道欢乐城喜悦庭6幢3212室 权益变动性质：股份增加 信息披露义务人声明 一、本报告书系信息披露义务人根据《中华人民共和国公司法》、《中华人民 共和国证券法》、《上市公司收购管理办法》、《北京证券交易所股票上市规则（ 试行）》、《公开发行证券的公司信息披露内容与格式准则第55号——北京证券交 易所上市公司权益变动报告书、上市公司收购报告书、要约收购报告书、被收购公 司董事会报告书》及其他相关法律、法规和部门规章的有关规定编写。 六、信息披露义务人承诺本报告书不存在虚假记载、误导性陈述或 ...

Revenue and Profit - The company's total revenue for 2023 is expected to be ¥174,876,443.46, a decrease of 10.38% compared to the previous year[6] - Net profit attributable to shareholders is projected at ¥11,726,670.74, down 70.90% year-on-year[6] - Basic earnings per share decreased to ¥0.16, representing an 80.49% decline compared to the previous year[4] Assets and Equity - Total assets at the end of the reporting period are estimated at ¥419,134,739.94, an increase of 0.35% year-on-year[5] - Shareholders' equity attributable to the company is expected to be ¥361,705,915.24, up 1.15% from the previous year[5] Expenses - Management expenses increased by ¥6,856,500 due to the completion of the JinHao Smart Medical Industrial Park and increased personnel[6] - R&D expenses rose by ¥7,990,000 as the company continues to invest in product development and talent acquisition[6] Impairment and Risks - The company recognized a credit impairment loss of ¥6,540,300 due to decreased customer demand and increased credit risk[6] - The decline in performance is attributed to global economic slowdown and reduced export trade growth[6] - The financial data presented is preliminary and has not been audited, cautioning investors about potential risks[8]

Financial Performance - The company's net profit attributable to shareholders is expected to be approximately ¥1,172.66 million, a decrease of 70.90% compared to ¥4,030.15 million in the same period last year[3]. - Revenue is projected to decline by 10.38% due to factors such as global economic development and a slowdown in export trade, with hearing aid product sales maintaining over 90% of total revenue[4]. Expenses - Management expenses increased by ¥6.8565 million due to the completion and operation of the JinHao Smart Medical Industrial Park and an increase in personnel[4]. - R&D expenses rose by ¥7.99 million as the company continues to invest in product development and talent acquisition[5]. Impairment and Risks - The company has recognized a credit impairment loss of ¥6.5403 million due to a decline in terminal demand from some customers amid high inflation and ongoing interest rate hikes in Europe and the U.S.[5]. - The performance forecast is based on preliminary calculations and has not been audited by an accounting firm, emphasizing the need for cautious investment decisions[6].

证券代码：872925 证券简称：锦好医疗 公告编号： 2024-005 惠州市锦好医疗科技股份有限公司 投资者关系活动记录表 公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、投资者关系活动类别 □特定对象调研 □业绩说明会 □媒体采访 现场参观 □新闻发布会 □分析师会议 □路演活动  其他（线上投资者调研会议） ...

| 日期 | 代码 | 简称 | 成交价 | 成交数量（股） | 买入营业部 | 卖出营业部 | | --- | --- | --- | --- | --- | --- | --- | | 2024-01- | 834261 | 一诺威 | | | 东吴证券股份有限公 | 中泰证券股份有限公 司龙口港城大道证券 | | | | | 5.64 | 100000 | 司济南明湖东路二部 | | | 31 | | | | | 营业部 | 营业部 | | | | | | | 中银国际证券股份有 | 东吴证券股份有限公 | | 2024-01- 31 | 836149 | 旭杰科技 | 4.54 | 100000 | 限公司中银苏州竹辉 | 司苏州星湖街证券营 | | | | | | | 路营业部 | 业部 | | 2024-01- | 834033 | 康普化学 | | | 海通证券股份有限公 | 海通证券股份有限公 司山西转型综合改革 | | 31 | | | 34.19 | 30000 | 司山西转型综合改革 | | | | | | | | 示范区分公司 | 示范区分公司 | | 2024-01- | 43051 ...

证券代码：872925 证券简称：锦好医疗 公告编号：2024-004 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 减持主体减持前基本情况 | 股东名称 | | 股东身份 | 持股数量（股） | 持股比例 | 当前持股股份来源 | | --- | --- | --- | --- | --- | --- | | 博尔乐远 | 持股 | 5%以上股东 | 5,040,002 | 5.1391% | 北交所上市前取得 | | 东有限公 | | | | | | | 司 | | | | | | 二、 减持计划的实施结果 （一） 股东因以下原因披露减持计划实施结果： √减持计划实施完毕 □减持时间区间届满 惠州市锦好医疗科技股份有限公司 持股 5%以上股东减持股份结果公告 三、 备查文件目录 《博尔乐远东有限公司减持结果告知函》 惠州市锦好医疗科技股份有限公司 董事会 2024 年 1 月 25 日 （二） 本次减持事项是否与股东此前已披露的计划、承诺一致 √是 □否 （三） 减持时间区间届满，是否未实施 ...

| 日期 | 代码 | 简称 | 成交价 | 成交数量（股） | 买入营业部 | 卖出营业部 | | --- | --- | --- | --- | --- | --- | --- | | 2024-01- | 831370 | 新安洁 | 3.5 | | 中信证券股份有限公 司上海漕溪北路证券 | 安信证券股份有限公 司上海黄浦区中山东 | | 24 | | | | 120000 | | | | | | | | | 营业部 | 二路证券营业部 | | 2024-01- 24 | 833171 | 国航远洋 | 4.5 | 860000 | 华福证券有限责任公 司福州五一北路证券 | 第一创业证券股份有 | | | | | | | 营业部 | 限公司上海分公司 | | 2024-01- 24 | 872925 | 锦好医疗 | 10.88 | | 华泰证券股份有限公 司上海长宁区仙霞路 | 广发证券股份有限公 | | | | | | 300000 | | 司惠州下埔路营业部 | | | | | | | 证券营业部 | | | 2024-01- | 873693 | | 33.21 | | 华泰证券股份有限公 ...

证券代码：872925 证券简称：锦好医疗 公告编号：2024-003 惠州市锦好医疗科技股份有限公司 关于股东持股情况变动的提示性公告 公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法 律责任。 一、本次权益变动的基本情况 2024 年 1 月 17 日，公司接到股东通知，公司股东博尔乐远东有限公司（以下简 称"博尔乐"）于 2024 年 1 月 17 日通过大宗交易减持公司股份 200,000 股。 本次权益变动前，博尔乐持有公司股份 5,040,002 股，持股比例 5.1391%。 本次权益变动后，博尔乐持有公司股份 4,840,002 股，持股比例 4.9352%。 相关权益变动情况如下： | 股东名称 | 股份 | | 本次变动前持有 | | 本次变动后持有 | | 权益变动 | | | 变动方式 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 性质 | | 股份情况 | | 股份情况 | | 日期 | | ...